The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease

Value in Health

Volumn 10, Issue 1, 2007, Pages 32-41

  Brennan, Alan ^a   Akehurst, Ron ^a   Davis, Sarah ^a   Sakai, Hana ^a   Abbott, Victoria ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Calcium carbonate; Cost effectiveness; End stage renal disease; Hyperphosphatemia; Lanthanum carbonate; Phosphorus

Indexed keywords

CALCIUM CARBONATE; LANTHANUM CARBONATE; PHOSPHORUS;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 33846504992     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00142.x     Document Type: Article

References (35)

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13(Suppl. 1):S37-40.
2. Mallick NP, Gokal R. Haemodialysis. Lancet 1999;353:737-42.
3. US Renal Data System (USRDS). Annual Data Report. Bethesda, MD: The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
4. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998;338:1428-37.
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
6. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
7. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000;54:318-24.
8. Eknoyan G, Levin A, Levin NW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1-201.
9. Kim J, Pisoni RL, Danese M, et al. Achievement of proposed NKF-K/DOQI™ bone metabolism and disease guidelines: results from the dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 2003;14:269A-70A.
10. Wills MR, Savory J. Aluminium poisoning. dialysis encephalopathy, osteomalacia, and anaemia. Lancet 1983;2:29-34.
11. Locatelli F, Cannata-Andia JB, Drüeke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-31.
12. Finn WF, Joy MS, Hladik GA, the Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201.
13. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Prac 2005;100:8-19.
14. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate. a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
15. Hutchison AJ, Speake M, Al Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004;19:1902-6.
16. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63(Suppl. 85):S73-8.
17. Manns B, Stevens L, Miskulin D, et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004;66:1239-47.
18. US Renal Data System (USRDS). 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
19. Ansell D, Feest T, Byrne C, Ahmad A, eds. UK Renal Registry Report 2003. Bristol: UK Renal Registry, 2003.
20. Center on the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Tufts-New England Medical Center, ICRHPS. Available from: http://www.tufts-nemc.org/careregistry/ [Last accessed April 20, 2005].
21. Kiberd BA. Should hepatitis C-infected kidneys be transplanted in the United States? Transplantation 1994;57:1068-72.
22. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-9.
23. Lawrence WF, Grist TM, Brazy PC. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis 1995;25:701-9.
24. Eastman RC, Javitt JC, Herman WH. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goat of normoglycemia. Diabetes Care 1997;20:735-44.
25. Diabetes Control & Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-15.
26. Katz DA, Crononwett JL. The cost-effectiveness of early surgery versus watchful waiting in the management of small abdominal aortic aneurysms. J Vasc Surg 1994;19:980-90.
27. US Food and Drug Administration/Center for Drug Evaluation and Research. Fosrenol Drug Product Label, October 2004. Available from: http://www.fda.gov
28. Shire Pharmaceuticals Group plc. Internal Study Report, 2004.
29. Grunberg SM, Boutin J, Ireland A, et al. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 1996;4:435-9.
30. OECD Health Data 2004, a Comparative Analysis of 30 Countries. Organisation for Economic Co-operation and Development, 2004.
31. Huybrechts KF, Caro JJ, Wilson MA, O'Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005;8:549-61.
32. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22:417-30.
33. Buxton MJ, West RR. Cost-benefit analysis of long-term haemodialysis for chronic renal failure. BMJ 1975;2:376-9.
34. Ludbrook A. A cost-effective analysis of the treatment of chronic renal failure. Appl Econ 1981;13:337-50.
35. Mowatt G, Vale L, Perez J, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end stage renal failure. Health Technol Assess 2003;7:1-174.